RU2001107853A - Substituted phenyl derivatives, their preparation and use - Google Patents
Substituted phenyl derivatives, their preparation and useInfo
- Publication number
- RU2001107853A RU2001107853A RU2001107853/04A RU2001107853A RU2001107853A RU 2001107853 A RU2001107853 A RU 2001107853A RU 2001107853/04 A RU2001107853/04 A RU 2001107853/04A RU 2001107853 A RU2001107853 A RU 2001107853A RU 2001107853 A RU2001107853 A RU 2001107853A
- Authority
- RU
- Russia
- Prior art keywords
- urea
- tetrazol
- phenyl
- bromo
- trifluoromethylphenyl
- Prior art date
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title claims 38
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 92
- -1 cyano, nitro, amino Chemical group 0.000 claims 53
- 239000004202 carbamide Substances 0.000 claims 46
- 150000001875 compounds Chemical class 0.000 claims 25
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 201000010099 disease Diseases 0.000 claims 10
- 125000005842 heteroatoms Chemical group 0.000 claims 9
- 210000000988 Bone and Bones Anatomy 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 208000008466 Metabolic Disease Diseases 0.000 claims 6
- 125000002252 acyl group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000011780 sodium chloride Substances 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 201000002674 obstructive nephropathy Diseases 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 206010048962 Brain oedema Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010061255 Ischaemia Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 210000002997 Osteoclasts Anatomy 0.000 claims 2
- 208000007056 Sickle Cell Anemia Diseases 0.000 claims 2
- 206010068760 Ulcers Diseases 0.000 claims 2
- 230000000172 allergic Effects 0.000 claims 2
- 230000001396 anti-anti-diuretic Effects 0.000 claims 2
- 125000005418 aryl aryl group Chemical group 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 201000008286 diarrhea Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 230000001882 diuretic Effects 0.000 claims 2
- 239000002934 diuretic Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- 230000002148 osteoclast Effects 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 231100000397 ulcer Toxicity 0.000 claims 2
- RIWIYKPEDBYULV-UHFFFAOYSA-N 1-(3-bromophenyl)-3-(2,3-difluorophenyl)urea Chemical compound FC1=CC=CC(NC(=O)NC=2C=C(Br)C=CC=2)=C1F RIWIYKPEDBYULV-UHFFFAOYSA-N 0.000 claims 1
- HNCHAANFUMUUOD-UHFFFAOYSA-N 1-(4-bromophenyl)-3-[4-bromo-2-(2H-tetrazol-5-yl)phenyl]urea Chemical compound C1=CC(Br)=CC=C1NC(=O)NC1=CC=C(Br)C=C1C1=NN=NN1 HNCHAANFUMUUOD-UHFFFAOYSA-N 0.000 claims 1
- KPKYNVZQOPNBIL-UHFFFAOYSA-N 1-[4-bromo-2-(2H-tetrazol-5-yl)phenyl]-3-(3,5-dichlorophenyl)urea Chemical compound ClC1=CC(Cl)=CC(NC(=O)NC=2C(=CC(Br)=CC=2)C=2NN=NN=2)=C1 KPKYNVZQOPNBIL-UHFFFAOYSA-N 0.000 claims 1
- PTWUMGQRIORASC-UHFFFAOYSA-N 1-[4-bromo-2-(2H-tetrazol-5-yl)phenyl]-3-[4-chloro-3-(trifluoromethyl)phenyl]urea Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(NC(=O)NC=2C(=CC(Br)=CC=2)C=2NN=NN=2)=C1 PTWUMGQRIORASC-UHFFFAOYSA-N 0.000 claims 1
- AMUHUGOLEGMWSS-UHFFFAOYSA-N 1-methylpiperazine-2-carboxamide Chemical compound CN1CCNCC1C(N)=O AMUHUGOLEGMWSS-UHFFFAOYSA-N 0.000 claims 1
- RQPVXOUSZLDZFI-UHFFFAOYSA-N 2-(phenylcarbamoylamino)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1NC(=O)NC1=CC=CC=C1 RQPVXOUSZLDZFI-UHFFFAOYSA-N 0.000 claims 1
- YOFUAJYJFAWCHH-UHFFFAOYSA-N 2-[2-oxo-3-[3-(trifluoromethyl)phenyl]imidazolidin-1-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1N1C(=O)N(C=2C=C(C=CC=2)C(F)(F)F)CC1 YOFUAJYJFAWCHH-UHFFFAOYSA-N 0.000 claims 1
- JKEHYLFSMVHHES-UHFFFAOYSA-N 2-[[methyl-[3-(trifluoromethyl)phenyl]carbamoyl]amino]benzoic acid Chemical compound C=1C=CC(C(F)(F)F)=CC=1N(C)C(=O)NC1=CC=CC=C1C(O)=O JKEHYLFSMVHHES-UHFFFAOYSA-N 0.000 claims 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 1
- CZAUOFXREFVFBI-UHFFFAOYSA-N 5-bromo-2-[[3-(trifluoromethyl)phenyl]carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC(Br)=CC=C1NC(=O)NC1=CC=CC(C(F)(F)F)=C1 CZAUOFXREFVFBI-UHFFFAOYSA-N 0.000 claims 1
- ZZSSXILLOUQSIX-UHFFFAOYSA-N 5-chloro-2-[[3-(trifluoromethyl)phenyl]carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC(Cl)=CC=C1NC(=O)NC1=CC=CC(C(F)(F)F)=C1 ZZSSXILLOUQSIX-UHFFFAOYSA-N 0.000 claims 1
- AUTSRTJPPGRBSE-UHFFFAOYSA-N 5-fluoro-2-[[3-(trifluoromethyl)phenyl]carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC(F)=CC=C1NC(=O)NC1=CC=CC(C(F)(F)F)=C1 AUTSRTJPPGRBSE-UHFFFAOYSA-N 0.000 claims 1
- 102000004310 Ion Channels Human genes 0.000 claims 1
- 108090000862 Ion Channels Proteins 0.000 claims 1
- 206010061289 Metastatic neoplasm Diseases 0.000 claims 1
- ZSRNFXQWCQXPSR-UHFFFAOYSA-N [4-(2-phenylphenyl)-2-(2H-tetrazol-5-yl)phenyl]urea Chemical compound NC(=O)NC1=CC=C(C=2C(=CC=CC=2)C=2C=CC=CC=2)C=C1C1=NN=NN1 ZSRNFXQWCQXPSR-UHFFFAOYSA-N 0.000 claims 1
- 230000002378 acidificating Effects 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 230000004097 bone metabolism Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000007796 conventional method Methods 0.000 claims 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
- 230000001394 metastastic Effects 0.000 claims 1
- 200000000023 metastatic cancer Diseases 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- LUBJCRLGQSPQNN-UHFFFAOYSA-N phenylurea Chemical compound NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 claims 1
- 0 CC=Nc1c(*)c(*)c(*)c(*)c1C Chemical compound CC=Nc1c(*)c(*)c(*)c(*)c1C 0.000 description 2
Claims (15)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA199801362 | 1998-10-22 | ||
DK199801362 | 1998-10-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2001107853A true RU2001107853A (en) | 2003-06-20 |
RU2218328C2 RU2218328C2 (en) | 2003-12-10 |
Family
ID=8104026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2001107853/04A RU2218328C2 (en) | 1998-10-22 | 1999-10-19 | Substituted phenyl derivatives, their preparing and application |
Country Status (28)
Country | Link |
---|---|
US (1) | US6706749B2 (en) |
EP (2) | EP1514867A3 (en) |
JP (2) | JP3960754B2 (en) |
KR (1) | KR100799892B1 (en) |
CN (1) | CN1263733C (en) |
AP (1) | AP2001002103A0 (en) |
AT (1) | ATE286021T1 (en) |
AU (1) | AU759275B2 (en) |
BR (1) | BR9914638A (en) |
CA (1) | CA2342626A1 (en) |
DE (1) | DE69922986T2 (en) |
EE (1) | EE04849B1 (en) |
ES (1) | ES2235522T3 (en) |
HK (1) | HK1040699A1 (en) |
HU (1) | HUP0103673A3 (en) |
IL (2) | IL141479A0 (en) |
IS (1) | IS2215B (en) |
NO (1) | NO20011956D0 (en) |
NZ (1) | NZ510098A (en) |
OA (1) | OA11665A (en) |
PL (1) | PL198852B1 (en) |
PT (1) | PT1123274E (en) |
RU (1) | RU2218328C2 (en) |
SK (1) | SK5222001A3 (en) |
TR (1) | TR200101126T2 (en) |
UA (1) | UA73284C2 (en) |
WO (1) | WO2000024707A1 (en) |
ZA (1) | ZA200101824B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA011085B1 (en) * | 2004-12-23 | 2008-12-30 | Кова Ко., Лтд. | Preventive or therapeutic agent for glaucoma |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10102977A1 (en) | 2001-01-23 | 2002-08-01 | Thomas Jentsch | Test system for the development of therapeutic agents, in particular active ingredients for the treatment of osteoporosis |
DK1360504T3 (en) * | 2001-01-23 | 2007-01-29 | Pharmos Bioscience As | Method of screening compounds for activity in the treatment of an osteoclast-related bone disease |
US20050080112A1 (en) * | 2001-06-22 | 2005-04-14 | Madsen Lars Siim | Compounds for use in disorders associated with mast cell or basophil acitvity |
JPWO2003014727A1 (en) * | 2001-08-08 | 2004-11-25 | 中外製薬株式会社 | Heart disease treatment |
US7087631B2 (en) | 2002-07-18 | 2006-08-08 | Inotek Pharmaceuticals Corporation | Aryltetrazole compounds, and compositions thereof |
US7078423B2 (en) | 2002-07-18 | 2006-07-18 | Inotek Pharmaceuticals Corporation | 5-Aryltetrazole compounds, compositions thereof, and uses therefor |
US7291603B2 (en) | 2002-07-24 | 2007-11-06 | Ptc Therapeutics, Inc. | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations |
IL166040A0 (en) * | 2002-08-01 | 2006-01-15 | Neurosearch As | Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy |
AU2003258491A1 (en) * | 2002-09-05 | 2004-03-29 | Neurosearch A/S | Amide derivatives and their use as chloride channel blockers |
CN100497302C (en) * | 2002-09-05 | 2009-06-10 | 神经研究公司 | Diarylurea derivatives and their use as chloride channel blockers |
AU2003280308A1 (en) | 2002-11-21 | 2004-06-15 | Neurosearch A/S | Aryl ureido derivatives and their medical use |
AU2003297441A1 (en) * | 2002-12-24 | 2004-07-22 | Arena Pharmaceuticals, Inc. | Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a |
US7691891B2 (en) | 2003-06-17 | 2010-04-06 | Neurosearch A/S | Diphenylurea derivatives and their use as chloride channel blockers |
BRPI0412263B1 (en) * | 2003-07-22 | 2019-10-15 | Arena Pharmaceuticals, Inc. | Diaryl and aryl heteroaryl urea derivatives, use and pharmaceutical composition containing them, as well as process for preparing said composition |
ATE415959T1 (en) | 2003-09-04 | 2008-12-15 | Neurosearch As | HERG1 CHANNEL OPENER FOR THE TREATMENT OF HEART ARRYTHMIA |
WO2005023238A1 (en) * | 2003-09-04 | 2005-03-17 | Poseidon Pharmaceuticals A/S | Erg channel openers for the treatment of hyperexcitability-related neuronal diseases |
WO2005103011A1 (en) * | 2004-03-23 | 2005-11-03 | Arena Pharmaceuticals, Inc. | Processes for preparing substituted n-aryl-n’-[3-(1h-pyrazol-5-yl) phenyl] ureas and intermediates thereof |
WO2005095360A1 (en) * | 2004-04-02 | 2005-10-13 | Prana Biotechnology Limited | Neurologically-active compounds |
EP1751097B1 (en) * | 2004-05-12 | 2009-12-30 | Proteotech, Inc. | Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies |
SA05260357B1 (en) | 2004-11-19 | 2008-09-08 | ارينا فارماسيتو تيكالز ، أنك | 3-phenyle-pyrazole derivatives as modulators of the 5-ht 2a serotonin receptor useful for the treatment of disorders related thereto |
US20080015223A1 (en) * | 2004-12-03 | 2008-01-17 | Arena Pharmaceuticals, Inc. | Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto |
EP1858877B1 (en) | 2005-01-14 | 2014-03-12 | Gilead Connecticut, Inc. | 1,3 substituted diaryl ureas as modulators of kinase activity |
CA2594563A1 (en) * | 2005-01-19 | 2006-07-27 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis or treatment of progressive multifocal leukoencephalopathy |
WO2007024294A2 (en) | 2005-05-03 | 2007-03-01 | Cgi Pharmaceuticals, Inc. | Certain substituted ureas, as modulators of kinase activity |
CA2646336A1 (en) * | 2006-03-14 | 2007-09-20 | Neurosearch A/S | Diphenylurea derivatives and their use as chloride channel blockers or bkca channel modulators |
EP2012789B1 (en) | 2006-04-14 | 2013-09-25 | Prana Biotechnology Limited | Method of treatment of age-related macular degeneration (AMD) |
JP5406018B2 (en) | 2006-05-18 | 2014-02-05 | アリーナ ファーマシューティカルズ, インコーポレイテッド | Primary amines as modulators of 5-HT2A serotonin receptors useful for the treatment of disorders associated with 5-HT2A serotonin receptors, and derivatives thereof |
MX2008014622A (en) | 2006-05-18 | 2008-11-28 | Arena Pharm Inc | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor. |
EP2027119A2 (en) | 2006-05-18 | 2009-02-25 | Arena Pharmaceuticals, Inc. | Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
TWI415845B (en) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
JP5393677B2 (en) | 2007-08-15 | 2014-01-22 | アリーナ ファーマシューティカルズ, インコーポレイテッド | Imidazo [1,2-a] pyridine derivatives as modulators of 5-HT2A serotonin receptors for the treatment of disorders associated with 5-HT2A serotonin receptors |
US20100286149A1 (en) * | 2007-11-26 | 2010-11-11 | Antonio Nardi | Novel benzamide derivatives useful as potassium channel modulators |
US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
CN102264354B (en) | 2008-10-28 | 2015-03-25 | 艾尼纳制药公司 | Compositions of 5-ht2a serotonin receptor modulator useful for treatment of disorders related thereto |
WO2011022028A2 (en) * | 2009-05-18 | 2011-02-24 | Tufts University | Small molecule antagonists of phosphatidylinositol-3, 4, 5-triphosphate (pip3) and uses thereof |
GB0915196D0 (en) | 2009-09-01 | 2009-10-07 | King S College London | Therapeutic compounds and their use |
US8980891B2 (en) | 2009-12-18 | 2015-03-17 | Arena Pharmaceuticals, Inc. | Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US20120208855A1 (en) * | 2010-07-12 | 2012-08-16 | Sanofi | Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders |
US9834537B2 (en) | 2013-11-27 | 2017-12-05 | Korea Institute Of Science And Technology | Compounds as chloride channel blocking agent |
WO2016001452A1 (en) * | 2014-07-04 | 2016-01-07 | Universität Zürich | Compounds, in particular for use in the treatment of a disease or condition for which a bromodomain inhibitor is indicated |
RU2017145976A (en) | 2015-06-12 | 2019-07-15 | Аксовант Сайенсиз Гмбх | Diaryl- and arylheteroarylurea derivatives applicable for the prevention and treatment of behavioral disturbances during the REM phase of sleep |
US10034859B2 (en) | 2015-07-15 | 2018-07-31 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
PL3622953T3 (en) | 2016-05-17 | 2021-08-16 | Scandion Oncology A/S | Combination treatment of cancer |
SG11202000230VA (en) | 2017-07-11 | 2020-02-27 | Vertex Pharma | Carboxamides as modulators of sodium channels |
WO2022056447A1 (en) * | 2020-09-14 | 2022-03-17 | Genzyme Corporation | Carboxylic acid-containing compounds as modulators of bis-phosphoglycerate mutase for the treatment of sickle cell disease |
AU2022293969A1 (en) | 2021-06-14 | 2023-12-14 | Scandion Oncology A/S | Methods of increasing the plasma drug exposure of anticancer agents |
EP4355324A1 (en) | 2021-06-14 | 2024-04-24 | Scandion Oncology A/S | Combination treatments for cancer patients and methods for identifying same |
EP4104834A1 (en) | 2021-06-14 | 2022-12-21 | Scandion Oncology A/S | Combination treatments for cancer patients and methods for identifying same |
TW202321205A (en) | 2021-07-16 | 2023-06-01 | 丹麥商斯坎丁腫瘤公司 | Thermodynamically stable form of sco-101 |
CN117229258A (en) * | 2022-06-07 | 2023-12-15 | 杭州壹瑞医药科技有限公司 | N-tetrazolyl aryl urea derivative and preparation method and application thereof |
WO2024013058A1 (en) | 2022-07-11 | 2024-01-18 | Scandion Oncology A/S | Salts of sco-101 and methods involving salts |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1055786A (en) * | 1963-07-12 | 1967-01-18 | Ici Ltd | Urea derivatives |
FR2100943A1 (en) * | 1970-07-23 | 1972-03-24 | Ici Ltd | O-carboylcarbanilides from anthranilic acid and substd - isocyanates - immuno-suppressive agents |
DE2928485A1 (en) * | 1979-07-14 | 1981-01-29 | Bayer Ag | USE OF UREA DERIVATIVES AS A MEDICINAL PRODUCT IN THE TREATMENT OF FATTY METABOLISM DISORDERS |
CA1156250A (en) * | 1979-10-15 | 1983-11-01 | Eastman Kodak Company | Cyan dye-forming couplers |
EP0210574B1 (en) | 1985-07-31 | 1991-10-23 | Hoechst Aktiengesellschaft | N-substituted 5-nitro anthranilic acids, process for their preparation, their use and pharmaceutical compositions based on these compounds |
US4889612A (en) | 1987-05-22 | 1989-12-26 | Abbott Laboratories | Ion-selective electrode having a non-metal sensing element |
US4921997A (en) * | 1988-06-15 | 1990-05-01 | Montefiore Medical Center | Method of synthesis and novel compounds for pharmaceutical uses |
JPH05504968A (en) | 1990-03-07 | 1993-07-29 | ローン―プーラン・ロレ・ソシエテ・アノニム | Glycinamide derivatives, their production and pharmaceuticals containing them |
US5489612A (en) | 1991-08-23 | 1996-02-06 | The University Of Alabama At Birmingham Research Foundation | Calixarene chloride-channel blockers |
US5273992A (en) | 1992-11-02 | 1993-12-28 | Beth Israel Hospital Assoc. Inc. | Method for reducing sickle erythrocyte dehydration and delaying the occurrence of erythrocyte sickling in-situ |
DK41193D0 (en) * | 1993-04-07 | 1993-04-07 | Neurosearch As | ion channel openers |
CA2137755C (en) * | 1994-06-07 | 2002-07-02 | William H. Waugh | Palliation of sickle cell disorders by phenylurea, benzylurea, or phenylethylurea or by a homolog ring-substituted with one methoxyl, methyl, or hydroxyl radical |
US5559151A (en) | 1994-11-30 | 1996-09-24 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of chloride channel blockers |
DE4447096C2 (en) * | 1994-12-29 | 1998-12-03 | Rehau Ag & Co | Stabilized chlorine-containing polymers and use of functional urea derivatives as stabilizers |
WO1996025157A1 (en) * | 1995-02-17 | 1996-08-22 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
US5773459A (en) * | 1995-06-07 | 1998-06-30 | Sugen, Inc. | Urea- and thiourea-type compounds |
CN1116288C (en) * | 1996-04-23 | 2003-07-30 | 沃泰克斯药物股份有限公司 | Urea derivatives as inhibitors of IMPDH enzyme |
JP4073489B2 (en) * | 1996-05-24 | 2008-04-09 | ニューロサーチ・アクティーゼルスカブ | PHENYL DERIVATIVE HAVING ACID GROUP, PROCESS FOR PRODUCING THE SAME, AND METHOD FOR USING THE SAME AS CHLORIDE CHANNEL BLOCKING AGENT |
NZ337976A (en) * | 1997-04-22 | 2001-05-25 | Neurosearch As | Substituted phenyl derivatives, their preparation and use |
US6093742A (en) * | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
DE1042305T1 (en) * | 1997-12-22 | 2001-04-19 | Bayer Ag | INHIBITION OF p38 KINASE USING SYMMETRIC AND ASYMMETRIC DIPHENYL UREAS |
-
1999
- 1999-10-19 BR BR9914638-0A patent/BR9914638A/en not_active Application Discontinuation
- 1999-10-19 TR TR2001/01126T patent/TR200101126T2/en unknown
- 1999-10-19 KR KR1020017004970A patent/KR100799892B1/en not_active IP Right Cessation
- 1999-10-19 OA OA1200100094A patent/OA11665A/en unknown
- 1999-10-19 SK SK522-2001A patent/SK5222001A3/en unknown
- 1999-10-19 NZ NZ510098A patent/NZ510098A/en unknown
- 1999-10-19 PL PL347371A patent/PL198852B1/en unknown
- 1999-10-19 ZA ZA200101824A patent/ZA200101824B/en unknown
- 1999-10-19 EP EP04105861A patent/EP1514867A3/en not_active Withdrawn
- 1999-10-19 ES ES99950505T patent/ES2235522T3/en not_active Expired - Lifetime
- 1999-10-19 AT AT99950505T patent/ATE286021T1/en not_active IP Right Cessation
- 1999-10-19 IL IL14147999A patent/IL141479A0/en active IP Right Grant
- 1999-10-19 RU RU2001107853/04A patent/RU2218328C2/en not_active IP Right Cessation
- 1999-10-19 UA UA2001021084A patent/UA73284C2/en unknown
- 1999-10-19 DE DE69922986T patent/DE69922986T2/en not_active Expired - Lifetime
- 1999-10-19 AP APAP/P/2001/002103A patent/AP2001002103A0/en unknown
- 1999-10-19 HU HU0103673A patent/HUP0103673A3/en unknown
- 1999-10-19 EE EEP200100185A patent/EE04849B1/en not_active IP Right Cessation
- 1999-10-19 AU AU63259/99A patent/AU759275B2/en not_active Ceased
- 1999-10-19 JP JP2000578279A patent/JP3960754B2/en not_active Expired - Fee Related
- 1999-10-19 CN CNB998117730A patent/CN1263733C/en not_active Expired - Fee Related
- 1999-10-19 WO PCT/DK1999/000575 patent/WO2000024707A1/en active IP Right Grant
- 1999-10-19 PT PT99950505T patent/PT1123274E/en unknown
- 1999-10-19 EP EP99950505A patent/EP1123274B1/en not_active Expired - Lifetime
- 1999-10-19 CA CA002342626A patent/CA2342626A1/en not_active Abandoned
-
2001
- 2001-02-16 IL IL141479A patent/IL141479A/en not_active IP Right Cessation
- 2001-03-02 IS IS5875A patent/IS2215B/en unknown
- 2001-04-19 US US09/837,166 patent/US6706749B2/en not_active Expired - Fee Related
- 2001-04-20 NO NO20011956A patent/NO20011956D0/en not_active Application Discontinuation
-
2002
- 2002-03-19 HK HK02102082A patent/HK1040699A1/en not_active IP Right Cessation
-
2003
- 2003-01-30 JP JP2003022576A patent/JP2003246773A/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA011085B1 (en) * | 2004-12-23 | 2008-12-30 | Кова Ко., Лтд. | Preventive or therapeutic agent for glaucoma |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2001107853A (en) | Substituted phenyl derivatives, their preparation and use | |
RU2218328C2 (en) | Substituted phenyl derivatives, their preparing and application | |
RU99124188A (en) | SUBSTITUTED PENYL DERIVATIVES, THEIR OBTAINING AND APPLICATION | |
RU2004130488A (en) | Pyrimidine derivatives | |
RU2017109719A (en) | METHODS FOR TREATING PROTOZOIC INFECTIONS | |
JP2007500226A5 (en) | ||
JP2022000482A5 (en) | ||
JP2005536475A5 (en) | ||
RU2009139087A (en) | 8-OXYCHINOLINE DERIVATIVES AS BRAKININ V2 RECEPTOR MODULATORS | |
HU211317A9 (en) | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids | |
RU2004127925A (en) | N3-Alkylated Benzimidazole Derivatives as Mek Inhibitors | |
CA2440037A1 (en) | Benzimidazole derivatives for modulating the rage receptor | |
JP2001526218A5 (en) | ||
RU2008146479A (en) | MATRIX METALLOPROTEINASE INHIBITORS | |
RU2006135084A (en) | PENTAFLUOROSULFANILY DERIVATIVES, THEIR PRODUCTION AND APPLICATION AS PHARMACEUTICAL AGENTS | |
RU2001135802A (en) | Bradykinin Receptor Antagonists | |
CN1216036A (en) | Novel tetralone or benzopyranone derivs and process for producing same | |
CA2099447A1 (en) | Angiotensin ii receptor antagonists for the treatment and prophylaxis of coronary heart disease | |
RU99120183A (en) | OXAZOLIDINONES AS ANTAGONISTS OF 5-HT2A RECEPTOR | |
RU2001111323A (en) | DERIVATIVES 2-PHENILPIRAN-4-SHE | |
RU98119076A (en) | DERIVATIVES OF 2- (3H) -OXASOLONE AND THEIR APPLICATION AS SOX-2 INHIBITORS | |
CN1265589A (en) | Enantiomers of 4-[[(cyanoimino)-[(1,2,2-trimethylpropyl) amino] methyl] amino] benzonitrile | |
RU2005105058A (en) | NEW ARILIMIDAZOLE DERIVATIVES, THEIR DRUGS AND THEIR THERAPEUTIC APPLICATIONS | |
RU2004126145A (en) | N - {[((2S) -4- (3,4-DIFLUORBENZENE) MORPHOLIN-2YL] -METHyl} -2- {3- [(METHYLSULPHONYL) AMINO] PHENIES L} ACETAMIDE AS A TREATMENT TREATMENT CCR-3 FOR TREATMENT | |
JP2003523995A5 (en) |